X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
treosulfan (170) 170
index medicus (154) 154
humans (127) 127
busulfan - analogs & derivatives (109) 109
female (104) 104
oncology (97) 97
male (94) 94
hematology (74) 74
transplantation (73) 73
middle aged (69) 69
adult (68) 68
aged (54) 54
chemotherapy (52) 52
busulfan - administration & dosage (51) 51
stem cells (51) 51
bone-marrow-transplantation (49) 49
stem-cell transplantation (46) 46
busulfan - therapeutic use (45) 45
hematopoietic stem cells (45) 45
transplantation conditioning - methods (42) 42
busulfan (41) 41
treatment outcome (41) 41
busulfan - adverse effects (40) 40
cancer (39) 39
fludarabine (38) 38
adolescent (37) 37
children (34) 34
hematopoietic stem cell transplantation (34) 34
pharmacology & pharmacy (34) 34
preparative regimen (34) 34
immunology (33) 33
antineoplastic agents, alkylating - therapeutic use (32) 32
transplantation, homologous (31) 31
child (30) 30
child, preschool (30) 30
disease-free survival (30) 30
stem cell transplantation (29) 29
vidarabine - analogs & derivatives (28) 28
antineoplastic combined chemotherapy protocols - therapeutic use (24) 24
care and treatment (24) 24
intravenous treosulfan (24) 24
pharmacokinetics (24) 24
conditioning regimen (23) 23
health aspects (23) 23
survival rate (23) 23
antineoplastic agents, alkylating - administration & dosage (22) 22
cyclophosphamide (22) 22
toxicity (22) 22
versus-host-disease (22) 22
animals (21) 21
research (21) 21
infant (20) 20
survival (20) 20
bone marrow (19) 19
recurrence (19) 19
acute myeloid-leukemia (18) 18
chimerism (18) 18
gemcitabine (18) 18
melanoma - drug therapy (18) 18
mortality (18) 18
patients (18) 18
risk (18) 18
therapy (18) 18
transplants & implants (18) 18
analysis (17) 17
busulfan - pharmacology (17) 17
hematopoietic stem cell transplantation - methods (17) 17
pediatrics (17) 17
survival analysis (17) 17
young adult (17) 17
busulfan - pharmacokinetics (16) 16
dose-response relationship, drug (16) 16
myelodysplastic syndrome (16) 16
transplantation conditioning (16) 16
vidarabine - administration & dosage (16) 16
aged, 80 and over (15) 15
antitumor-activity (15) 15
bone marrow transplantation (15) 15
conditioning (15) 15
graft-versus-host reaction (15) 15
retrospective studies (15) 15
hematopoietic stem cell transplantation - adverse effects (14) 14
liver (14) 14
medicine & public health (14) 14
medicine, research & experimental (14) 14
mice (14) 14
ovarian cancer (14) 14
ovarian neoplasms - drug therapy (14) 14
trial (14) 14
uveal melanoma (14) 14
antineoplastic agents, alkylating - adverse effects (13) 13
antineoplastic combined chemotherapy protocols - adverse effects (13) 13
cisplatin (13) 13
deoxycytidine - analogs & derivatives (13) 13
disease (13) 13
follow-up studies (13) 13
high-dose treosulfan (13) 13
leukemia (13) 13
ocular melanoma (13) 13
ovarian-cancer (13) 13
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Immunology, ISSN 0271-9142, 08/2017, Volume 37, Issue 6, p. 511
Journal Article
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, ISSN 1083-8791, 05/2019
The prognosis of resistant or relapsing children with neuroblastoma remains very poor, and the search for new therapies is ongoing. In this analysis, we... 
Journal Article
Oncotarget, ISSN 1949-2553, 04/2018, Volume 9, Issue 27, pp. 19317 - 19327
Treosulfan (L-treitol-1,4-bis-methanesulfonate) has been increasingly incorporated as a main conditioning protocol for hematopoietic stem cell transplantation... 
Gonadal toxicity | Treosulfan | Busulfan
Journal Article
Pharmaceutical Development and Technology, ISSN 1083-7450, 05/2019, Volume 24, Issue 5, pp. 639 - 648
Introduction: Treosulfan is an alkylating agent that is used for the treatment of ovarian cancer and for conditioning prior to stem cell transplantation. It is... 
formulation | HL-60 cell line | Treosulfan | drug toxicity | HPLC | drug stability | PREPARATIVE REGIMEN | INTRAVENOUS TREOSULFAN | REFRACTOMETRIC DETECTION | ACUTE MYELOID-LEUKEMIA | DRUG-RESISTANCE | OVARIAN-CANCER | MYELODYSPLASTIC SYNDROME | CONDITIONING REGIMEN | PEDIATRIC-PATIENTS | PHARMACOLOGY & PHARMACY | STEM-CELL TRANSPLANTATION
Journal Article
BONE MARROW TRANSPLANTATION, ISSN 0268-3369, 07/2017, Volume 52, pp. S98 - S99
Conference Proceeding
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 09/2018, Volume 104, Issue 3, pp. 575 - 583
A treosulfan (Treo)‐based conditioning regimen prior to hematopoietic stem cell transplantation (HSCT) has been successfully used in treating hematological... 
TOTAL-BODY IRRADIATION | PREPARATIVE REGIMEN | HIGH-DOSE TREOSULFAN | BONE-MARROW-TRANSPLANTATION | POPULATION PHARMACOKINETICS | PHARMACOLOGY & PHARMACY | ACUTE MYELOID-LEUKEMIA | INTRAVENOUS BUSULFAN | HEMATOLOGIC MALIGNANCIES | CONDITIONING REGIMEN | MYELODYSPLASTIC SYNDROMES
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 09/2019, Volume 85, Issue 9, pp. 2033 - 2044
Treosulfan is an alkylating agent increasingly used prior to hematopoietic stem cell transplantation (HSCT). The aim of this study was to develop a population... 
paediatric patients | treosulfan | conditioning regimen | haematopoietic stem cell transplantation | population pharmacokinetics | Medicine, Experimental | Medical research | Transplantation | Analysis | Hematopoietic stem cells | Stem cells | Index Medicus | Original
Journal Article
Journal of Hematology and Oncology, ISSN 1756-8722, 04/2019, Volume 12, Issue 1, pp. 44 - 44
Journal Article
Bone Marrow Transplantation, ISSN 0268-3369, 04/2013, Volume 48, Issue 4, pp. 491 - 501
Journal Article
Bone Marrow Transplantation, ISSN 0268-3369, 12/2011, Volume 46, Issue 12, pp. 1510 - 1518
This retrospective analysis evaluated 51 children (0.7-17 years; median eight) with high-risk or advanced hematological malignancies, including 18 (35%)... 
childhood hematological malignancies | preparative regimen | allogeneic hematopoietic SCT | Treosulfan | INTRAVENOUS TREOSULFAN | RISK-FACTORS | BONE-MARROW-TRANSPLANTATION | ACUTE MYELOID-LEUKEMIA | IMMUNOLOGY | I DOSE-ESCALATION | NONMALIGNANT DISEASES | TRANSPLANTATION | ONCOLOGY | HEPATIC VENOOCCLUSIVE DISEASE | ACUTE LYMPHOBLASTIC-LEUKEMIA | QUALITY-OF-LIFE | STEM-CELL TRANSPLANTATION | HEMATOLOGY | Hematologic Neoplasms - therapy | Busulfan - analogs & derivatives | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Hematologic Neoplasms - mortality | Humans | Child, Preschool | Etoposide - administration & dosage | Infant | Male | Survival Rate | Vidarabine - analogs & derivatives | Antineoplastic Agents, Alkylating - administration & dosage | Busulfan - administration & dosage | Transplantation, Homologous | Disease-Free Survival | Melphalan - administration & dosage | Adolescent | Female | Retrospective Studies | Vidarabine - administration & dosage | Transplantation Conditioning | Child | Carmustine - administration & dosage | Antimitotic agents | Complications and side effects | Care and treatment | Patient outcomes | Dosage and administration | Transplantation | Acute lymphocytic leukemia | Research | Antineoplastic agents | Hematopoietic stem cells | Index Medicus
Journal Article
Leukemia & Lymphoma, ISSN 1042-8194, 06/2019, Volume 60, Issue 7, pp. 1758 - 1766
We analyzed outcomes of 126 patients with hematologic malignancies, who relapsed after first allogeneic hematopoietic cell transplantation (HCT) and received... 
second allotransplant | Allogeneic hematopoietic cell transplantation | post-transplant relapse | CRITERIA | TREOSULFAN | CORD BLOOD | FLUDARABINE | ACUTE-LEUKEMIA PATIENTS | WORKING GROUP | ONCOLOGY | RECOMMENDATIONS | MALIGNANCIES | OUTCOMES | HEMATOLOGY | PROBABILITIES
Journal Article